ADC Therapeutics (ADCT) Stock Price, News & Analysis

Company Overview

ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC technology is designed to use antibodies to selectively deliver potent cytotoxic agents to cancer cells, with the goal of limiting exposure to healthy tissue.

The company’s lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed at the CD19 antigen. Zynlonta is approved in the United States for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. ADC Therapeutics is also advancing a pipeline of investigational ADC candidates for hematologic malignancies and solid tumors.

ADC Therapeutics was founded in 2011 and is headquartered in Lausanne, Switzerland, with operations and commercial activities supporting its oncology programs in the United States and other markets. The company’s research and development efforts are focused on expanding its ADC platform and developing additional targeted cancer therapies.

Key Stats

• Today's Range: $1.63 to $1.86
• 50-Day Range: $0.96 to $1.87
• 52-Week Range: $0.78 to $4.98
• Volume: 3.32 million shs
• Average Volume: 1.39 million shs
• Market Capitalization: $215.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Hold

ADC Therapeutics Stock Analysis - MarketRank™

ADC Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 726th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

ADC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

ADC Therapeutics has a consensus price target of $5.00, representing about 196.7% upside from its current price of $1.69.

Amount of Analyst Coverage

ADC Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ADC Therapeutics are expected to grow in the coming year, from ($0.80) to ($0.76) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ADC Therapeutics is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ADC Therapeutics is -2.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.69% of the float of ADC Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

ADC Therapeutics has a short interest ratio ("days to cover") of 4.37.

Change versus previous month

Short interest in ADC Therapeutics has recently increased by 27.93%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ADC Therapeutics does not currently pay a dividend.

Dividend Growth

ADC Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.06

News Sentiment

ADC Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 10 news articles for ADC Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ADC Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.10% of the stock of ADC Therapeutics is held by insiders.

Percentage Held by Institutions

41.10% of the stock of ADC Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/13/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:ADCT
• CIK: 1771910
• Web: www.adctherapeutics.com
• Phone: 41-21-653-0200
• Fax: N/A
• Employees: 191
• Year Founded: 2010

Price Target and Rating

• Average Price Target for ADC Therapeutics: $5.00
• High Price Target: $8.00
• Low Price Target: $2.00
• Potential Upside/Downside: +196.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.66)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$142.62 million
• Net Margins: -121.77%
• Pretax Margin: -122.28%
• Return on Equity: N/A
• Return on Assets: -32.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.03
• Quick Ratio: 2.97

Sales & Book Value

• Annual Sales: $81.36 million
• Price / Sales: 2.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.50) per share
• Price / Book: -1.12

Miscellaneous

• Outstanding Shares: 127,670,000
• Free Float: 121,157,000
• Market Cap: $215.12 million
• Optionable: Optionable
• Beta: 1.86